Comparison the Effect of Empaglifluzin and Linagliptin on the Albuminuria of diabetic patients

Phase 3

• Conditions: Diabetic Nephropathy.; Type 2 diabetes mellitus with diabetic nephropathy; E11.21

• Registration Number: IRCT20200722048176N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age over 30 years and under 75 years
Type 2 diabetes
The patient has microalbuminuria

Exclusion Criteria

HbA1C>9%
uncontrolled blood pressure
uncontrolled blood sugar
heart failure
chronic liver disease
GFR<30
presence of hematuria
signs of active urinary and renal infection
uinary catheter
High stages of nephropathy
other kidney diseases that cause albuminuria such as glomerulonephritis
acute hospital conditions

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of mean albuminuria between the group receiving Empagliflozin with the group receiving Linagliptin at the beginning and end of the study. Timepoint: At the beginning of the study and ninety days after starting the drug. Method of measurement: Measurement of urinary microalbumin exceretion sampling.